Integrum CE marks Neuromotus™ – a novel system for phantom limb pain treatment

Report this content

Integrum has CE marked Neuromotus, a novel system which employs virtual and augmented reality along with artificial intelligence algorithms for the treatment of phantom limb pain.

Phantom limb pain (PLP) is a deteriorating condition for which there has been no effective treatment. The prevalence of PLP among amputees is reported to be between 42-80%. Patients suffering from PLP have historically been neglected, mostly because of the lack of an effective treatment, and the poor understanding of the condition. These patients are often left to be permanently medicated with the all the downsides of using strong pain killers or resigned to a life with chronic pain.

Neuromotus™ provides a solution for people suffering phantom limb pain. A recently published study in the Lancet (the top ranked European scientific journal) showed that our product is an effective option even for patients where all other treatments have failed. Patients who had suffered of chronic phantom limb pain for decades without any effective treatment option were relieved from their constant pain and reduced their dependency on pain medications after using our product. These improvements were still observable 6 months after treatment which is of great importance for the clinical relevance for treatments of chronic conditions.

Integrum is currently present at the health care conference, Vitalis 2019, held 21-23rd May 2019 at Svenska Mässan, Gothenburg, to demonstrate the system. Dr. Max Ortiz Catalan will speak about the scientific background and clinical findings with this technology in the same conference on 22nd May at 2 pm.

” Neuromotus™ echoes with Integrum’s commitment to improving life for people with amputation. We are glad to know that our product can help people around the world suffering from phantom limb pain and will enable them to have a better life. I am happy to see that we already have orders from several clinics and research centers in Europe”, says María López, CEO at Integrum.




For further information contact

María López, CEO. Cell: +46 708 46 10 69, Email:

This information is such that Integrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8.00 CET on May 21, 2019.

Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser Bank is the Company's Certified Adviser

Certified Adviser

Erik Penser Bank AB, Certified Adviser can be reached at +46 8 463 8000 or

About Integrum

Integrum provides innovative solutions for bone-anchored prostheses. Integrum’s OPRATM implant system improves quality of life for amputees through higher prosthetic functionality, improved comfort and improved mobility. With 20 years’ experience from 500 surgeries in 13 countries, Integrum is a global leader in bone anchored protheses. The company’s share (INTEG B) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Advisor. Learn more at


Documents & Links